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Abstract
MicroRNAs (miRNAs) are a class of endogenous non-coding small RNAs that are evolutionarily conserved and widely
distributed among species. Their major function is to negatively regulate mRNA target genes, and miRNA expression has been
found to be deregulated in all human cancers, where miRNAs play critical roles in tumorigenesis, functioning either as tumor
suppressors or as oncogenes. This review provides a current overview of the connection between miRNAs and cancer by
covering the recent advances in miRNA involvement in human cancer including initiation, growth, invasion, and metastasis.
We will also highlight the literature where application of miRNAs has created the foundation for the development of potential
future miRNA therapy.
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Introduction
MicroRNAs (miRNAs) are small non-coding RNAs
belonging to a novel class of negative regulators
that control gene expression by imperfect base pairing
to the 3  untranslated region (3  UTR) of a target
mRNA, leading to a protein translation inhibition or
mRNA degradation (1). MiRNAs are initially tran-
scribed by RNA polymerase II as long primary pre-
cursors which are rapidly processed by an
endonucleolytic multistep process into 18–22nt long
mature miRNAs (2). Once produced, miRNAs are
loaded into the RNA-induced silencing complex
(RISC) and guide the degradation or translational
repression of the target mRNA(3). MiRNAs are found
in the majority of multicellular and complex eukar-
yotes; it is currently estimated that miRNAs represent
1% of the predicted genes and that up to 10%–30% of
human transcriptome is a direct target of miRNAs,
indicating a pivotal role for miRNAs in almost every
biological process, including cell cycle regulation, cell
growth, apoptosis, cell differentiation, and stress
response (1). However, genetic analysis of Caenorhab-
ditis elegans highlighted that only 10% of individual
miRNA knock-outs have a distinct morphological and
developmental defect (4), illustrating the existence of
functional redundancy among miRNAs or miRNA-
regulated pathways. This redundancy shows that miR-
NAs may have evolved to control and reﬁne speciﬁc
aspects of terminal differentiation programs. Indeed,
another important aspect of microRNA activity is
represented by their ability to target thousands of genes
per single miRNA, based on the 5  end-restricted
complementarity between animal miRNAs and
mRNA targets (only ﬁve to eight nucleotides of perfect
complementarity, termed ‘seed sequence’). This target
multiplicity may explain their ability to control several
mRNAs that function in the same or similar processes.
For example, miR-221 and miR-222 have been shown
to activate cell proliferation by repressing a series of
tumor suppressors, all of which are involved in cell
cycleinhibition,likep27(5),itsactivator FOXO3a (6),
p57 (7), BMF (8), PTEN (9), and APAF1 (10).
Given their essential role in all the aspects of the
cellular life, it is not surprising that miRNAs were
found to cover important roles in tumorigenesis, and,
since this discovery, over 5000 publications link
miRNAstocancer,includingmorethan1000reviews.
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molecular roles of miRNAs in cancer and metastasis
by highlighting the most promising advances for the
use of miRNAs in the clinical setting, both as direct
and adjuvant chemotherapeutic agents.
MiRNAs in cancer
Genome-wide miRNA expression proﬁling analyses
have reported a general dysregulation of miRNA
expression in all tumors (11). To date, over
1000 miRNAs have been reported in humans (miR-
base: 1527 at November 2011), and hundreds of
them map to chromosomic regions that are known to
be altered in human cancer, such as loss of hetero-
zygosity regions (LOH) (e.g. miR-15a/16-1), ampli-
ﬁed regions (e.g. miR-17–92 cluster, miR-155), and
breakpoint regions and fragile sites (FRA) (e.g. let-
7 family members) (12). Published studies have
deﬁn e dt h a te l e v a t e de x p r e s s i o no fs o m em i R N A s
(oncogenes) as well as down-regulation of others
(tumor-suppressors) accompanies carcinogenesis
and correlates with the development of cancer-
associated phenotypes.
The ﬁrst evidence of miR involvement in cancer
came from our laboratory in 2004. We identiﬁed
that the miR-15 and miR-16 genomic locus is
heterozygously deleted in 68% of all patients with
B-cell chronic lymphocytic leukemia (CLL) (13).
Loss of miR-15 and miR-16 reﬂects their tumor-
suppressor function via uncontrolled expression of
their anti-apoptotic target protein BCL2 in an in vitro
model as well as in patient specimens of B-CLL (14).
Furthermore, a sequencing-based screen for miRNAs
dysregulated in familial CLL patients identiﬁed a
germ-line mutation in the primary precursor of
miR-15a/16-1 that impairs their processing, highlight-
ing that not only deletions but also mutations may lead
to miRNAloss of function (15). The importance of
genetic lesions reducing miR-15/16-1 cluster expres-
sion in CLL was furthermore conﬁrmed by
the identiﬁcation of a point mutation located in
the 3  ﬂanking region of miR-16 that reduces
miR-16 expression in a naturally occurring CLL
mouse model, the New Zealand black (NZB) mouse,
that develops a hematological disorder similar to the
human CLL (16). Even more deﬁnitive genetic evi-
dence of the tumor-suppressive effects of miR-15 and
miR-16 camerecentlyfrom the Dalla-Faveralab where
miR-15/16 knock-out mice were generated (17).
Targeted deletion of miR-15 and miR-16 in mice at
the age of 18 months recapitulates the spectrum of
CLL-associated lymphoproliferations in humans,
including CLL, CD5(+) monoclonal B-cell lympho-
cytosis, and CD5- non-Hodgkin lymphomas (17).
Speciﬁcally, miR-15a/16-1 deletion accelerates the
proliferation of both human and mouse B-cells by
modulating the expression of genes controlling cell
cycle progression like cyclin D3, cyclin E, CDK6,
CHK1, and MCM5. However, the same authors
also demonstrated that the size of 13q14 deletions,
where the miR-15/16-1 cluster is located, inﬂuences
the phenotype of lymphoproliferative disorders and
potentially the severity of disease, suggesting a tumor
suppressor function for genetic elements besides
miR-15a/16-1 and their host gene DLEU2 (18). In
fact, an additional deletion of a 0.69 mb-large region
telomeric to miR-15/16-1 increased the appearance of
CLL, and mice seemed to succumb to their disease
faster than miR-15/16-1-deleted mice. Deletion of the
miR-15/16-1 cluster also occurs in other forms of
tumors, such as multiple myeloma (19) and prostate
cancer (20), indicating that the loss of these miRNAs
could be relevant to other pathogenic events. In fact,
the De Maria group demonstrated that, in prostate
cancer, miR-15a/miR-16 levels are strongly down-
regulated in the vast majority of cases (up to 85% of
the analyzed samples) (20). Interestingly, intrapros-
tatic injection of miRNA antisense RNA oligonucleo-
tide (‘antagomirs’)s p e c i ﬁc to miR-15a and miR-16 in
6-week-old male BALB/c mice resulted in marked
hyperplasia, and knock-down of miR-15a and
miR-16 promoted survival, proliferation, and invasive-
ness of untransformed prostate cells, which became
tumorigenic in immunodeﬁcient NOD-SCID mice
(20). Furthermore, they also demonstrated that
miR-15 and miR-16 are down-regulated in ﬁbro-
blasts surrounding the prostate tumors. Increased
miR-15 and miR-16 expression in cancer-associated
ﬁbroblasts impaired tumor growth and expansion of
prostate tumors in xenograft models through the
reduced post-transcriptional repression of Fgf-2 and
its receptor Fgfr1 (21).
Similar to the down-regulation of the miR-15/16-1
cluster, another miRNA frequently lost in cancer is
represented by the miR-34 family. These miRNAs,
miR-34a on chromosome 1p36 and the miR-34b/c
cluster on chromosome 11q23, are frequently deleted
in neuroblastoma, breast, pancreas, hepatic, and colon
carcinoma (22). Loss of expression of the miR-34b/
c cluster has also been associated with the hypermethy-
lation of their CpG-associated promoter region in
gastric cancer, while the same chromosomal region
was not methylated in normal gastric mucosa (23).
The miR-34 family has been shown to be transcrip-
tionally activated by p53, and it represents one of the
main effectors of p53-induced apoptosis, senescence,
and cell cycle arrest. These effects are achieved by
repressing the expression of multiple oncogenes
such as Notch-1 (24), Notch-2 (24), HMGA2 (24),
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the anti-apoptotic factor BCL2 (28), and the
p53 deacetylase SIRT1 (29). Recently, miR-34 family
knock-out mice have been generated, and no obvious
developmental or pathological abnormalities were
observed at up to 12 months of age (30). However,
the authors showed that miR-34-deﬁcient mouse
embryonic ﬁbroblasts accelerate the reprogramming,
not as expected through cell proliferation, but instead,
at least partly, by post-transcriptional derepression of
pluripotency genes, such as Sox2, N-Myc, and Nanog
(30). Many othermiRNAs have been reported to act as
tumor suppressors (Table I) by inhibiting tumor
growth when expressed ectopically in vitro or in vivo;
however, their bona ﬁde tumor suppressor role is still
missing. Examples include miR-26 (31,32), miR-143/
145 cluster (33), miR-181 family (34), miR-200 family
(35), miR-203 (10,36), miR-31 (37), and miR-192/
194/215 (38).
Although there seems to be a general trend towards
down-regulation of microRNAs in cancer (39), many
different miRNAs follow the opposite pattern and,
based on their ability to initiate or accelerate cancer,
are named ‘oncomiRs’. The ﬁrst evidence of an
oncogenic miRNAappeared in 2005 when the
Mendell lab demonstrated that Myc can directly
induce the expression of the polycistronic cluster
miR-17/92 (40). By using a reconstituted mouse
model of Myc-induced lymphoma expressing a trun-
cated version of the miR-17/92 cluster in hematopoi-
etic cells, the authors showed an accelerated tumor
development probably due to an anti-apoptotic mech-
anism associated with the suppression of their direct
targets, such as inhibitors of proliferation CDKN1A
(41), direct regulators of the apoptosis PTEN (42),
and BCL2L11 (also known as BIM) (43). This cluster
has been shown to be up-regulated in many solid
tumors such as breast, stomach, prostate, lung, and
pancreas tumors (44), and genetic deletion of the
miR-17/92 cluster in mice highlighted their impor-
tance in B-cell development, as homozygous deletion
of the cluster results in premature death of B-cells at
the pro-B and pre-B stages, resulting in lymphopenia
(45). Interestingly, functional dissection of the
miR-17/92 cluster in the context of B-cell transfor-
mation in vivo revealed that miR-19a and b mediate
the oncogenic activity of the entire cluster, at least in
part, by targeting the tumor suppressor PTEN and
thereby activating Akt-mTOR signaling to promote
cell survival (42).
Another microRNAwith oncogenic activity is repre-
sented by miR-21, which is highly expressed in the
majority of human malignancies thus far analyzed,
including breast cancer (46,47), glioblastoma (48,49),
hepatocellular carcinoma (50), cholangiocarcinoma
(51),lungcancer(52),tonguesquamouscellcarcinoma
(53), esophageal cancer (54), stomach cancer (55),
colorectal cancer (56), chronic myelogenous leukemia
(57), cervical cancer (58), and prostate cancer (59).
Experimental data indicate that miR-21 also plays a
crucial role in tumor cell proliferation, apoptosis, and
invasion, consistent with miR-21’s ability to repress
important tumor suppressors such as PTEN (50),
PDCD4 (56), TPM-1 (60), Tap-63 (61), SPRY2
(62), and hMSH2 (63).
Recently, the Slack lab generated the ﬁrst condi-
tional knock-in of miR-21 overexpressing mice that
showed a 15–30-fold induction of miR-21 (64). These
mice developed a severe pre-B-cell lymphoma, but
when miR-21 was reduced to endogenous levels the
mouse tumors completely disappeared, deﬁning the
concept of ‘oncomiR addition’ (64). Interestingly, a
4–6-fold overexpression of miR-21 resulted in no
obvious phenotype; however, miR-21 overexpression
potentiates the lung tumorigenesis of a constitutively
activated KRAS proto-oncogene (65). Another in vivo
evidence that miR-21 exerts an oncogenic function
came from the DMBA-TPA skin carcinogenesis
model used by Ma et al. on miR-21-null mice (66).
The miR-21 mice showed a signiﬁcant reduction in
papilloma formation compared with wild-type mice,
with miR-21-null mice exhibiting an increase in cel-
lular apoptosis and decrease in cell proliferation that is
explained by the up-regulation of the miR-21 targets
Spry1 (62), Pten (50), and Pdcd4 (56).
Many other miRNAs have been reported to act as
oncogenes (Table II) by inducing tumor growth,
aggressiveness, and resistance to chemotherapy
when expressed ectopically in vitro or in vivo:
miR-155, miR-221, and miR-222 cluster, miR-9
and miR-103/107 family.
MiRNAs in metastasis
Accumulating data have pointed to a central regula-
tory role of miRNAs in the acquisition of invasive
abilities and generation of the malignant phenotype
that consists of loss of cellular adhesion, acquisition of
cell motility, intra- and extravasation, and ﬁnally
proliferation at a distant site. The ﬁrst example of a
‘metastamiR’ is represented by miR-10a (67).
Weinberg’s group demonstrated that miR-10a is over-
expressed in about 50% of metastatic breast cancers
and is transcriptionally activated by the pro-metastatic
transcription factor TWIST1. Speciﬁcally, they dem-
onstrated that miR-10a did not affect cell proliferation
but instead promoted in vitro and in vivo migration,
invasion, and metastasis of otherwise non-invasive
breast cancer cells by repressing the homeobox
protein D10, a transcription factor already known
204 G. Di Leva et al.Table I. Tumor-suppressor miRs.
miR Targets Tumor Impact on metastasis Description
miR-15/16 BCL2 CLL BCL2 repression by these microRNAs
induces apoptosis in a leukemic cell line
model
COX-2 Colon cancer miR-16 as a central post-
transcriptional regulator of COX-2 and
shows the ability of elevated levels of HuR
to antagonize miR-16 function
CHEK1 Follicular lymphoma Distinct microRNA proﬁles are associated
with an increased proliferative capacity
and a ‘late’ germinal center
B-cell phenotype
CEBPb, CDC25a,
CCNE1
Fibroblast Upon cell cycle re-entry, the rapid decay
of miR-16 alleviates repression of target
genes, allowing proper resumption of the
cell cycle
VEGF, VEGFR2,
FGFR1
Fibroblast miR-16 plays important roles in regulating
cell-intrinsic angiogenic activity of
endothelial cells
FGF2, FGFR1 Cancer-associated
ﬁbroblast
Down-regulation of miR-15 and
miR-16 in cancer-associated ﬁbroblasts
(CAFs) promotes tumor growth and
progression
CCNE1 miR-15 and miR-16 families as novel
transcriptional targets of E2F, which, in
turn, modulates E2F activity
FGFR1, PI3KCa,
MDM4, VEGFa
Multiple myeloma Deletion of miR-15/16 is commonly
observed in early stages of multiple
myeloma
WIP1 Role of miR-16 in the regulation of
Wip1 phosphatase in the DNA damage
response and mammary tumorigenesis
BMI-1 Ovarian cancer Bmi-1 is down-regulated by miR-15a or
miR-16 expression and leads to reduction
in ovarian cancer cell proliferation and
clonal growth
CCND1, CCND2,
CCNE1
Lung cancer Overexpression of miR-15/16 induces
arrest in G(1)-G(0)
miR-31 ITGA5, RDX, RhoA,
FZD3, M-RIP, MMP16
Breast cancer Suppresses miR-31 uses multiple mechanisms to
oppose metastasis
SATB2 Cancer-associated
ﬁbroblast
New insights into tumor–stroma
interaction and involvement of miR-31 in
regulation of tumor cell motility
miR-34 SIRT1 Colon cancer miR-34 suppression of SIRT1 leads to
apoptosis only in colon cancer cells with
wild-type p53
BCL2, NOTCH,
HMGA2
miR-34-mediated suppression of self-
renewal is related to the direct modulation
of the downstream targets Bcl-2, Notch,
and HMGA2
MYC Fibroblast During senescence, miR-34a targets the
proto-oncogene MYC and co-
ordinately controls a set of cell cycle
regulators
AXL Lung cancer Axl receptor is regulated by miR-34a and
miR-199a/b, suppressed by promoter
methylation in solid cancer
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miR Targets Tumor Impact on metastasis Description
MET Ovarian cancer MET is a critical effector of p53, and
inhibition of MET may be an effective
antimetastatic approach to treat cancers
with p53 mutations
NANOG, SOX2,
MYCN
Embryonic
ﬁbroblast
Suppression of reprogramming by
miR-34a due to repression of pluripotency
genes
SNAIL Colon cancer A new link between p53, miR-34, and
Snail1 in the regulation of cancer cell
EMT programs
miR-143/145 KRAS, RREB1 Pancreatic cancer miR-143/miR-145 are suppressed by
KRAS through RREB1, revealing a feed-
forward mechanism that potentiates Ras
signaling
KRAS, MYC, CCND2,
CDK6, E2F3
Colon cancer EGFR suppresses miR-143 and
miR-145 in murine models of colon
cancer
BCL2 Cervical cancer Promotion of apoptosis by
miR-143 through the suppression of
BCL2
PAI1 Bladder cancer miR-145 and PAI1 as clinically relevant
biomarkers in bladder cancer
PRC1, PLK1 Liposarcoma The down-regulation of PRC1 and its
docking partner PLK1 suggests that
miR-143 inhibits cytokinesis in these cells
MLL-AF4 ALL Therapeutic promise of up-
regulating miR-143 expression for MLL-
AF4 B-cell ALL
MMP-13 Osteosarcoma Down-regulation of miR-143 correlates
with the lung metastasis of human
osteosarcoma cells by promoting cellular
invasion, probably via MMP-13
up-regulation
ERK5 Burkitt lymphoma miRs-143 and -145 may be useful as
biomarkers that differentiate
B-cell malignant cells from normal cells
Let-7 family KRAS Lung cancer The let-7 family negatively regulates let-
60/RAS in C. elegans and lung tumors
HMGA2 Chromosomal translocations associated
with human tumors disrupt repression of
high mobility group A2 (Hmga2) by let-
7 miRNA
MYC Burkitt lymphoma Dysregulation of let-7 participates in
genesis and maintenance of Burkitt
lymphoma and other MYC-
dysregulated cancers
IMP-1 Let-7-oncofetal proteins could be novel
therapeutic targets and potential
biomarkers for cancer treatment
DICER Existence of a regulatory loop to regulate
the equilibrated state of Dicer and various
miRNAs
CDC-34 Fibroblast Let-7 represses Cdc34, stabilizes
Wee1 kinase, and increases a fraction of
cells in G(2)/M in primary ﬁbroblasts
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miR-31 is highly down-regulated in metastatic breast
cancer, and its overexpression strongly reduces met-
astatic spreading without affecting primary tumor
growth (37). MiR-31’s actions on already-seeded
lung metastases can be mediated via co-ordinate
repression of a cohort of metastasis-promoting genes,
including ITGA5, RDX, and RhoA.
The invasion–metastasis cascade, the multistep
process whereby tumor cells disseminate from their
Table I. (Continued).
miR Targets Tumor Impact on metastasis Description
IL6 Breast cancer Inﬂammation activates a positive feedback
loop that maintains the epigenetic
transformed state
E2F2, CCND2 Prostate cancer Let-7a acts as a tumor suppressor in
prostate cancer by down-
regulating E2F2 and CCND2
BCL-XL Liver cancer Let-7 suppresses Bcl-xL expression in
hepatocellular carcinomas and potentiates
sorafenib-induced apoptosis
PLCg1 Breast cancer Tumor-suppressor function by negatively
regulating EGF-driven cell invasion,
viability, and cell cycle progression in
breast cancer
miR-200 family ZEB1, ZEB2 Breast cancer Suppresses Down-regulation of the miR-200 family
may be an important step in tumor
progression
ERRFI-1 Bladder cancer miR-200 is sufﬁcient to restore EGFR
dependency at least in some of the
mesenchymal bladder cancer cells
ZEB1, CTNNB1 Nasopharyngeal
carcinoma
The inhibitory effects of miR-200a on cell
growth, migration, and invasion are
mediated by distinct targets and pathways
BMI-1 Pancreatic cancer ZEB1 links EMT and stemness
maintenance by suppressing the
miR-200 family and thereby promotes
migration
PLCg1 Breast cancer Tumor-suppressor function by negatively
regulating EGF-driven cell invasion,
viability, and cell cycle progression in
breast cancer
FAP1 miR-200c sensitizes cells to apoptosis
mediated by CD95
SUZ12 Breast cancer The miR-200b-Suz12-cadherin pathway
is important for cancer stem cell growth
and invasive ability
FLT1/VEGFR1 Lung cancer miR-200 suppresses lung
adenocarcinoma metastasis by targeting
Flt1 in tumor cells
JAG1, MALM2,
MALM3
These ﬁndings explain increased Notch
signaling in some types of cancers, where
mutations in Notch pathway genes are
rare
FN1, LEPR, NTRK2,
ARHGAP19
Breast and
endometrial cancer
miR-200c actively represses a program of
mesenchymal and neuronal genes
involved in cell motility and anoikis
resistance
p38a Ovarian cancer miR-200a-dependent stress signature
correlates with improved survival of
patients in response to treatment
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miR Targets Tumor Impact on metastasis Description
miR-106a ~ 363,
miR-106b ~ 25
BIM, p21 Gastric cancer The miR-106b-25 cluster is involved in
E2F1 post-transcriptional regulation and
may play a key role in the development of
TGFb resistance in gastric cancer
E2F1 Prostate cancer microRNA expression becomes altered
with the development and progression of
prostate cancer. Some of these
microRNAs regulate the expression of
cancer-related genes in prostate cancer
cells
PTEN Prostate cancer Proto-oncogenic miRNA-
dependent network for PTEN regulation
miR-21 PTEN Cholangiocarcinoma Promotes miR-21 modulates gemcitabine-
induced apoptosis by phosphatase and the
tensin homolog deleted on chromosome
10 (PTEN)-dependent activation of
PI3-kinase signaling
TPM1 Breast cancer Suppression of miR-21 can inhibit tumor
growth
PDCD4 Breast cancer The tumor suppressor protein
programmed cell death 4 (PDCD4) is
regulated by miR-21, and it has been
demonstrated that PDCD4 is a
functionally important target for
miR-21 in breast cancer cells
SPRY1 miR-21-null mice show a signiﬁcant
reduction in papilloma formation
compared with wild-type mice due to the
up-regulation of its tumor-
suppressor targets
RECK, TIMP3 Glioblastoma The inhibition of miR-21 provides a novel
therapeutic approach for ‘physiological’
modulation of multiple proteins whose
expression is deregulated in cancer
p63, JMY,
TOPORS,
TP53BP2, DAXX,
HNRPK, TGFbRII
Glioblastoma miR-21 targets multiple important
components of p53, transforming growth
factor-b (TGFb), and mitochondrial
apoptosis tumor-suppressive pathways
MARKS Prostate cancer miR-21 could promote apoptosis
resistance, motility, and invasion in
prostate cancer cells
ANP32A, SACA4 Prostate cancer
miR-10a/10b HOXB1, HOXB3 Pancreatic cancer Promotes miR-10a is a key mediator of metastatic
behavior in pancreatic cancer that
regulates metastasis via suppression of
HOXB1 and HOXB3
HOXD10 Breast cancer TWIST transcription factor induces
expression of a speciﬁc microRNA that
suppresses its direct target and in turn
activates another pro-metastatic gene,
leading to tumor cell invasion and
metastasis
KLF4 Esophageal cancer A signiﬁcant correlation of miR-10b level
with cell motility and invasiveness
TIAM1 Breast cancer A mechanism for the regulation of
Tiam1-mediated Rac activation in breast
cancer cells
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miR Targets Tumor Impact on metastasis Description
Nf1 Ewing’s sarcoma miR-10b may play an important role in
NF1 tumorigenesis through targeting
neuroﬁbromin and RAS signaling
miR-107/103 DICER Breast cancer Promotes Dicer inhibition drifts epithelial cancer
toward a less-differentiated, mesenchymal
fate to foster metastasis
miR-9 PRDM1/Blimp-1 Lymphomas Promotes miRNA-mediated down-regulation of
PRDM1/Blimp-1 may contribute to the
phenotype maintenance and pathogenesis
of lymphoma cells by interfering with
normal B-cell terminal differentiation
CDH1 Breast cancer
CAMTA Glioblastoma miR-9 is highly expressed in glioblastoma
cancer stem cells and reduces the levels of
CAMTA tumor-suppressor
miR-17–92 TSP-1, CTGF Colon Promotes Up-regulated in colonocytes coexpressing
K-Ras, c-Myc and p53 impaired activity
E2F2, E2F3 Prostate/Burkitt
lymphoma/
testis carcinoma/
Presence of an autoregulatory feedback
loop between E2F factors and miR-17/92
BIM, PTEN c-Myc-induced
lymphoma
Transgenic mice with higher expression of
miR-17/92 in lymphocytes
HIF1a Lung cancer Intricate and ﬁnely tuned circuit involving
c-myc, miR-17/92, and HIF1a
PTPRO Cervix tumor cell
line
PTPRO gene is co-regulated by both
E2F1 and miR-17/92 at transcriptional
and post-transcriptional level, respectively
p63 Myeloid cells miR-92 increases cell proliferation by
negative regulation of an isoform of the
cell cycle regulator p63
BIM, PTEN,
PRKAA1, PPP2R5e
T-cell acute
lymphoblastic
leukemia
Functional genomics approach reveals a
co-ordinate clamp-down on several
regulators of phosphatidylinositol-3-OH
kinase-related survival signals by the
leukemogenic miR-19
JAK1 Endothelial cells The miR-17/92 family may provide an
interesting therapeutic perspective
speciﬁcally to enhance therapeutic
angiogenesis
HBP1 Breast cancer The miR-17/92 cluster plays an important
role in breast cancer cell invasion and
migration by suppressing HBP1 and
subsequently activating Wnt/b-catenin
p21(WAF1) Ras-induced senes-
cent ﬁbroblasts
Disruption of senescence by miR-17/92 or
its miR-17/20a components leads to
enhanced oncogenic transformation by
activated Ras in primary human cells
TGFbII SA4 Glioblastoma miR-17/92 attenuates the TGFb signaling
pathway to shut down clusterin
expression, thereby stimulating
angiogenesis and tumor cell growth
MnSOD, GPX2,
TRXR2
Prostate miR-17/92 may suppress tumorigenicity
of prostate cancer through inhibition of
mitochondrial antioxidant enzymes
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miR Targets Tumor Impact on metastasis Description
miR-221/222 p27
kip1 Glioblastoma, pros-
tate and thyroid
carcinoma
Promotes Certain cancer cell lines require high
activity of miR-221/222 to maintain low
p27
kip1 levels and continuous proliferation
p57
kip2 Normal ﬁbroblast Up-regulation of miR-221/222 is tightly
linked to the initiation of S phase with
growth factor signaling pathways that
stimulate cell proliferation
PTEN, TIMP3 Non-small cell lung
cancer and
hepatocellular
carcinoma
miR-221/222, by targeting PTEN and
TIMP3 tumor suppressors, induce
TRAIL resistance and enhance cellular
migration. The MET oncogene is
involved in miR-221/222 activation
through the c-Jun transcription factor
FOXO3A Breast cancer The miR-221/222 cluster targets
FOXO3A to suppress p27
kip1 also at a
transcriptional level
KIT Endothelial cells Interaction between miR-222 and c-Kit is
likely to be part of a complex circuit that
controls the ability of endothelial cells to
form new capillaries
ESR1 Breast cancer Modulation of ERa is associated with
antiestrogen therapy
PUMA Glioblastoma miR-221/222 directly regulate apoptosis
by targeting PUMA in glioblastoma
TRSP1 Breast cancer miR-221/222 promote EMT and
contribute to the more aggressive clinical
behavior of basal-like breast cancers
PTPm Glioblastoma miR-221/222 regulate glioma
tumorigenesis at least in part through the
control of PTPm protein expression
DICER Breast cancer Dicer is low in ERa-negative breast
cancers, since such cells express high
miR-221/222
APAF1 Non-small cell lung
cancer
miR-221/222 are modulated by both
epidermal growth factor (EGF) and MET
receptors, and, by targeting APAF1,
miR-221/222 are responsible for geﬁtinib
resistance
miR-155 SOCS1 Breast cancer miR-155 is an oncomiR in breast cancer,
and it has been suggested that
miR-155 may serve as a bridge between
inﬂammation and cancer
CEBPB, PU.1,
CUTL1, PICALM
AML miR-155 as a contributor to physiological
GM expansion during inﬂammation and
to certain pathological features associated
with AML
BACH1, ZIC3 The induction of miR-155 by EBV
contributes to EBV-mediated signaling in
part through the modulation of
transcriptional regulatory factors
ETS1, MEIS1 Human cord blood
CD34+
miR-155 is required for megakaryocytic
proliferation and differentiation
C-MAF Lymphocytes bic/microRNA-155 plays a key role in the
homeostasis and function of the immune
system
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ment, can be explained molecularly by epithelial-to-
mesenchymal transition (EMT). During EMT, an
epithelial neoplastic cell loses cell adhesion by repres-
sing E-cadherin expression, and thereby the cell
increases its motility. Numerous studies have shown
that different miRNAs are modulated during EMT,
and one of the best-studied examples is represented
by the miR-200 family. These miRs are commonly
lost in aggressive tumors such as lung, prostate, and
pancreatic cancer. It has been shown that miR-200
family members directly target ZEB1 and ZEB2,
transcription repressors of E-cadherin (68). In fact,
in the highly aggressive mouse lung cancer model
where KRAS is constitutively activated and p53 func-
tion is perturbed, miR-200 ectopic expression pre-
vented metastasis by repressing ZEB1 and ZEB2 and
preventing E-cadherin down-regulation (69). How-
ever, overexpression of the miR-200 family is associ-
ated with an increased risk of metastasis in breast
cancer, and this overexpression promotes metastatic
colonization in mouse models, phenotypes that can-
not be explained by E-cadherin expression alone (70).
By using proteomic proﬁling of the targets of
MET-inducing miR-200, the authors discovered
that miR-200 globally targets secreted proteins in
breast cancer cells. Between the 38 modulated target
genes, Sec23a, which is involved in transporting pro-
tein cargo from the endoplasmic reticulum to the
Golgi, shows a superior association with human met-
astatic breast cancer as compared to the currently
recognized miR-200 targets ZEB1 and the EMT
marker E-cadherin. EMT is ﬁrst acquired in the onset
of transmigration and then reversed (mesenchymal-
epithelial transition (MET)) in the new metastatic
site. Korpal et al. have shown that the miR-200 status
predicts predisposition of the cancer to successful
metastasis (70).
Another important study in the comprehension of
miRNA involvement in metastatic spread came from
the Massague lab, which has discovered that
miR-335, miR-126, and miR-206 are lost in human
lung and bone metastatic cells (71). Overexpression
of all three miRs suppressed the metastasis to lungs
and bone in mice. Although miR-126 inhibits tumor
growth and cell proliferation, miR-335 speciﬁcally
suppresses metastatic invasion by repressing the tran-
scription factor SOX4 and the extracellular matrix
Table II. (Continued).
miR Targets Tumor Impact on metastasis Description
HGAL Diffuse large
B-cell lymphoma
Cell dissemination and aggressiveness is a
phenotype of DLBCL typically expressing
high levels of miR-155 and lacking HGAL
expression
JMJD1A Nasopharyngeal
carcinoma
Up-regulation of miR-155 is partly driven
by LMP1 and LMP2A, and results in
down-regulation of JMJD1A, associated
with N stage and poor prognosis
WEE1 Breast cancer miR-155 enhances mutation rates by
decreasing the efﬁciency of DNA
safeguard mechanisms by targeting
of cell cycle regulators such as WEE1
TP53INP1 Pancreatic cancer TP53INP1 expression is repressed by the
oncogenic micro RNA miR-155, which is
overexpressed in pancreatic carcinoma
cells
SMAD1, SA5,
HIVEP2, CEBPB,
RUNX2, MYO10
Role for miR-155 in controlling BMP-
mediated cellular processes
FOXO3a Breast cancer Molecular links between miR-155 and
FOXO3a affect cell survival and response
to chemotherapy in breast cancer
hMSH2, hMSH6,
and hMLH1
Colon cancer Inactivation of mismatch repair is induced
by miR-155
SMAD5 Diffuse large
B-cell lymphoma
Highlighted a hitherto unappreciated role
of SA5 in lymphoma biology and deﬁned a
unique mechanism used by cancer cells to
escape TGFb’s growth-inhibitory effects
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miR-126 in the metastatic setting was recently deﬁned
by the Tavazoie group (72). They revealed that
endogenous miR-126 non-cell-autonomously regu-
lates endothelial cell recruitment to metastatic breast
cancer cells, in vitro and in vivo. Speciﬁcally, it sup-
presses metastatic endothelial recruitment, metastatic
angiogenesis, and metastatic colonization through co-
ordinate targeting of IGFBP2, PITPNC1, and
MERTK—novel pro-angiogenic genes and biomar-
kers of human metastasis.
New therapeutic approaches using miRNAs
The strong involvement of miRNAs in cancer appear-
ance, development, and progression provides a ratio-
nale for the therapeutic approach to miRNAs in
cancer treatment. During the years of miRNA
research, several strategies have been pursued, and
they can be recapitulated essentially in miRNA-
based therapy and miRNA-adjuvant therapy. The
ﬁrst approach will consist in reducing/increasing
miRNA levels (oncomiRs/tumor suppressor) and/or
interfering with the miRNA/mRNA interaction. As a
therapeutic possibility, miRNAs may be used as single
molecules or in a combinatorial way to target one or
multiple genes. For example, if a mutation is altering
the binding site for a miRNA, combining two or three
miRNAs can overcome the therapy unresponsiveness.
In addition, a combination of antagomiRs for onco-
miRs and miRNA mimics for tumor-suppressors may
represent a future approach. The ﬁrst example to be
cited in this area is the therapeutic use of let-7 mole-
cules in lung cancer. Let-7 has been shown to be
down-regulated in a large fraction of human cancers,
and low levels of hsa-let-7a expression are correlated
with poor survival of lung cancer patients (44,73).
Intratumoral injection of liposome-pre-let-7 mole-
cules in preformed lung tumor xenografts resulted
in the strong inhibition of overall tumor growth (74).
However, this delivery route might be inadequate in a
clinical setting, as peripheral tumor cells remained
present and showed limited knock-down of let-7 tar-
gets by immunohistochemistry. Another approach
with potential for translation into clinical settings is
the use of a neutral lipid emulsion (NLE). NLE has
shown tumor-inhibitory effects of let-7 NLE formula-
tions in a mouse model of lung cancer (a transgenic
mouse with a constitutively activated KRAS) with an
already established lung tumor (75). Another inter-
esting approach of miRNA-based therapies came
from Dr Mendell’s lab. MiR-26a is strongly down-
regulated in hepatocellular carcinoma (HCC) as com-
pared with paired non-cancerous tissues, and
miR-26a’s low expression is associated with a shorter
overall survival but a better response to interferon
therapy (76). Mendell’s lab demonstrated that sys-
temic delivery of a miR-26a-expressing adenoviral
particle via tail intravenous injections into a MYC-
induced hepatocellular carcinoma mouse model
resulted in inhibition of cancer cell proliferation,
induction of tumor-speciﬁc apoptosis, and dramatic
protection from disease progression, without toxicity
(77). However, the therapeutic approach of miR-26a
needs to be carefully considered based on the fact that
miR-26a has been found to be up-regulated in T-
ALL patients and its expression enhanced leukemo-
genesis in a mouse model of T-ALL by suppressing
the levels of PTEN and BIM tumor suppressor pro-
tein (77).
A recent work by Hatziapostolou and co-workers
deﬁned a new player in hepatocarcinogenesis and new
potential targets for the treatment of HCC (78). The
authors identiﬁed the existence of a positive feed-
back loop involving miR-24/miR-629/HNF4alpha/
miR-124/STAT3/IL-6R, in which perturbations
amplifyandperpetuatetheknock-downof HNF4alpha,
thereby inducing liver cancer. To test the relevance of
this novel inﬂammatory circuitry in vivo,t h e y
delivered miR-124 to the liver during diethylnitrosa-
mine (DEN)-induced hepatocarcinogenesis by using
tail injection of a miR-124 precursor liposome particle.
NotonlydidmiR-124reducethenumberofcarcinogen-
inducedtumorsby90%whenadministeredthroughout
theentirestudy,butitalsoledtoastriking80%decrease
whentreatmentwasstartedonly4weeksbeforesacriﬁce.
Even considering that therapeutic success in mouse
modelsisnotalwaysreproducibleinhumans,thisstudy
demonstratedtheefﬁcacyofmiR-124inthetreatmentof
liver cancer, and more importantly it opens the possi-
bility of using miR-124 therapy in the advanced stages
of HCC.
As previously stated, only the ‘seed sequence’ of a
miRNA is required to identify the appropriate mRNA
target, and miRNA‘target multiplicity’ is the natural
consequence of the small number of bases required
for miRNA function. Therefore, blocking the func-
tion of a single miRNA that is dysregulated in a
neoplastic state can have a major effect on disease
progression, because it will reactivate the expression
of a large fraction of genes. However, this reactivation
is not a simple task, as different miRNAs can target
the same sequence and miRNAs have identical seeds
but differ in the non-seed region. In fact, the tradi-
tional 15-mer antagomiR would target more than the
seed sequence, thereby generating the potential for
large, off-target inhibition of other miRNAs. The
solution appears to be selectively inhibiting miRNAs
using only the seed as a target. Sakari Kauppinen and
colleagues described an important new strategy for
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the functional consequences of targeting only the seed
sequence (79). They found that targeting the seed
region with a perfectly matched 8-base antimiR
potently inhibited miR-21 function and resulted in
up-regulation of a miR-21 target protein (79). More-
over, by targeting the seed region of let-7, they showed
how it is possible to block the function of an entire
family of microRNAs. A key feature of this approach
for future therapy is the simple systemic delivery; in
fact, intravenously injected tiny LNAs (locked nucleic
acid: chemically modiﬁed ribonucleotides) are taken
up by a range of mouse tissues, such as breast, lung,
and liver, which leads to long-lasting silencing of
miRNA function.
The second clinical application of miRNAs is
related to a more therapeutic value of miRNAs as
acute, rather than chronic, adjuvant targets. This
application is essentially supported by the numerous
studies describing the modulation of cell sensitivity to
chemotherapeutic agents after miRNA expression
modulation. A majority of these studies note the
identiﬁcation of modulated miRNAs in cells resistant
to chemotherapeutic drugs. In this regard, the
ﬁrst story that we would like to illustrate came from
our laboratory and describes the involvement of
the miR-221 and miR-222 cluster in TNF-related
apoptosis-inducing ligand (TRAIL)- and geﬁtinib-
resistance of non-small cell lung cancer (NSCLC)
(10,80,9). In 2005, our lab addressed the implication
of miRNAs in TRAIL-resistance of non-small cell
lung carcinoma, and we found that miR-221 and
miR-222 were markedly up-regulated in TRAIL-
resistant and semi-resistant cells compared to
TRAIL-sensitive NSCLC cells. Speciﬁcally, we dem-
onstrated that silencing p27
kip1 but not Kit, both
functional targets of miR-221 and miR-222, increased
resistance to TRAIL (80). This result supports well
the involvement of miR-221 and miR-222 in deter-
mining the TRAIL-resistant/sensitive phenotype in
NSCLC cells mainly by miR-221 and miR-222 inter-
fering with p27
kip1 expression and TRAIL-induced
caspase machinery. Recently, we also reported that
the hepatocyte growth factor receptor (MET) onco-
gene, through c-Jun transcriptional activation, up-
regulates miR-221 and miR-222 expression, which,
in turn, by targeting PTEN and TIMP3, confers
resistance to TRAIL-induced cell death and enhances
tumorigenicity of lung and liver cancer cells (82). The
results suggest that therapeutic intervention involving
the use of miRNAs should not only sensitize tumor
cells to drug-inducing apoptosis, but also inhibit their
survival, proliferation, and invasion. In our most
recent manuscript, we explored the involvement of
MET-modulated miR-221 and miR-222 in the
development of de novo and acquired resistance of
lung cancer cells to tyrosine kinase inhibitors, such as
geﬁtinib, the ﬁrst line of treatment for EGFR-
positive lung cancer patients (10). We demonstrated
that these two miRNAs are regulated by both MET
and EGFR receptors in lung cancer cells, and more
importantly, that their expression levels are down-
regulated upon geﬁtinib treatment only in geﬁtinib-
sensitive cells but not in resistant cells because of
MET overexpression. We also demonstrated that
geﬁtinib resistance could be overcome by MET inhi-
bitors, which down-regulate miR-221 and
miR-222 and sensitize lung cancer cells to geﬁtinib,
or by anti-miR-221 and anti-miR-222, which strongly
increase geﬁtinib sensitivity in vitro and in xenograft
mouse models in vivo (10). Another interesting appli-
cation of miR-221 and miR-222 on drug resistance
has been described in tamoxifen resistance in breast
cancer. Tamoxifen is one of the most widely used
selective estrogen receptor modulators in breast can-
cer therapy for estrogen receptor-positive patients.
One of the main problems related to its use is the
appearance of tamoxifen resistance in a large fraction
of patients who initially respond to the therapy.
Majumder’s group demonstrated in 2008 that
miR-221 and miR-222 are the most modulated
miRNAs in cells with acquired resistance to tamoxifen
(81). Interestingly, ectopic expression of miR-221
and miR-222 rendered the parental cells resistant
to tamoxifen, and the effect was partially related to
the down-regulation of the cell cycle inhibitor p27
kip1,
a known target of miR-221 and miR-222.
Up-regulation of miR-221 and miR-222 has also
been implicated in resistance to drugs such as fulves-
trant (82) and cisplatin (83) in breast cancer,
castration-resistant prostate cancer (84), TRAIL-
resistant non-small cell lung cancer cells (80), and
radiation-resistant gastric carcinoma cells (85).
Another interesting story that relates microRNA
expression to chemoresistance is represented by the
ability of miR-21 to modulate the sensitivity of cancer
cells to 5-ﬂuoruracil (5-FU). High levels of miR-21
were correlated with a very low response to therapy
and poor outcome in colorectal cancer patients (86);
the low response to the drug is partially associated to
reduced levels of core mismatch repair mutator genes
(63). Interestingly, inhibition of miR-21 expression
was able to sensitize cells to 5-FU, suggesting that
miR-21 inhibition may represent a future way to
overcome cell resistance to traditional chemotherapy
(63). Like miR-21, miR-34 has also been shown to
modulate cancer cell sensitivity to 5-FU (87). In this
case, ectopic expression of miR-34 in colorectal can-
cer cells inhibited cell proliferation and sensitized
cancer cells to 5-FU. However, miR-34 inhibition
MicroRNAs: new players in cancer 213has been shown to enhance the apoptotic response to
bortezomib in Myc-transformed B-cells, clearly dem-
onstrating that miRNA involvement in chemotherapy
is context-dependent (88).
Conclusion
MiRNAs continue to reveal high diversity and com-
plexity in their biological functions and involvement
in disease. However, despite remarkable recent prog-
ress, the connection between cancer and miRNAs
remains incompletely understood, and many open
questions remain with regard to the possible applica-
tion of miRNAs in therapy. First, based on the
miRNA target multiplicity and tissue-dependent
effects, one of the main goals of future miRNA
research must be the identiﬁcation of the widespread
effects on the transcriptome of every single miRNA.
To this aim, genome-wide analyses will need to delin-
eate the global alterations in miRNA genes or copy
number alterations in various human tumors in order
to identify all of the putative tumor-suppressor and
oncogenic miRNAs. At the same time, more sophis-
ticated in vivo models are needed to identify and
deﬁne miRNA functions. Because miRNAs can
have widespread effects on the transcriptome, their
full biological properties are unlikely to be explained
by the suppression of a single or few proteins. In fact,
the major challenge is to deﬁne all of the mRNA
targets and cancer-related pathways that are con-
trolled by the dysregulated miRNAs in neoplasia.
Unmistakably, miRNAs have a role in cancer, and
the major challenge is to recognize the impact on the
networks rather than on a few isolated targets. With
this aim, new sophisticated computational
target prediction methods will be helpful. Although
miRNAs only moderately suppress their targets,
miRNAs could exert both strong and broad effects,
largelybecause they suppress manygenes and because
they are implicated in multiple feedback loops with
other regulators of gene expression. Exploring the
roles of miRNAs in these intimate cross-talks will
help us to understand the causes of cancer and other
diseases and in creating new alternative therapeutics.
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